reports
Genmab Commences Tender Offer for All Issued and Outstanding Common Sh...
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. Media ReleaseCOPENHAGEN, Denmark; October 21, 2025 (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“Purchaser”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) of (Nasdaq: MRUS) (“Merus”) for $97.00 per Common Share in cash (the “Offer Consideration”), less any applicable withholding taxes and without interest. The Offer is being made pursuant to the previously...
Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conferenc...
Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conference call on 4 Nov 2025 at 11.00 CET Tuesday, 4 November 2025 at 11:00 - 12:00am CETIn connection with the publication of Coloplast’s interim financial results for FY 2024/25, to be released same day around 07.00am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the ...
- ABGSC Healthcare Research
- Morten Larsen
Genmab Announces New Data Demonstrating Investigational Rinatabart Ses...
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expressionA Phase 3 trial in endometrial cancer is underwayU.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometria...
DHT Holdings, Inc. to announce third quarter 2025 results on Wednesday...
DHT Holdings, Inc. to announce third quarter 2025 results on Wednesday, October 29, 2025 HAMILTON, BERMUDA, October 15, 2025 - DHT Holdings, Inc. (NYSE: DHT or the “Company”) will release its third quarter 2025 results after market close on Wednesday, October 29, 2025. The Company will host a conference call and webcast, which will include a slide presentation, at 8:00 a.m. EST/14:00 CET on Thursday, October 30, 2025, to discuss the results for the quarter. To access the conference call the participants are required to register in advance of the conference using this link: Upon regist...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarte...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025 Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 14, 2025 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,...
DHT Holdings, Inc. Business Update
DHT Holdings, Inc. Business Update HAMILTON, BERMUDA, October 14, 2025 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today provides the following business update: For the third quarter of 2025, the Company estimates time charter equivalent earnings for its fleet at $40,500 per day, comprising of $38,700 per day for the Company’s VLCCs operating in the spot market and $42,800 per day for the Company’s VLCCs on time charter. The estimated time charter equivalent earnings are based on 1,951 revenue days for the third quarter, of which 1,068 days are spot days. Thus far in the four...
DHT Statement Relating to October 10, 2025 China Ministry of Transport...
DHT Statement Relating to October 10, 2025 China Ministry of Transport Announcement HAMILTON, BERMUDA, October 13, 2025 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today made the following statement in reference to the announcement on October 10, 2025 by the Ministry of Transport in China relating the collection of special port fees from US-linked vessels. Each vessel in the Company’s fleet is directly owned by a non-U.S. entity, was built in a non-U.S. jurisdiction, does not fly the U.S. flag and is operated from management companies in Monaco, Norway, Singapore and India. D...
DHT Holdings, Inc. announces appointment of Mr. Svein Moxnes Harfjeld ...
DHT Holdings, Inc. announces appointment of Mr. Svein Moxnes Harfjeld to the Board of Directors HAMILTON, BERMUDA, October 13, 2025 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today announced the appointment of Svein Moxnes Harfjeld to the Board of Directors, effective immediately: Mr. Harfjeld currently serves as President and Chief Executive Officer of DHT Holdings, a position he has held since 2010 and will continue to hold. Chairman of the Board, Mr. Erik A. Lind stated: "With his over 30 years of experience in the global shipping industry, Mr. Harfjeld brings additional...
- ABGSC Shipping & Transport Research
- Martin Mauseth
- Petter Haugen
- ABGSC Shipping & Transport Research
- Olav Bakke
- Petter Haugen
Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den k...
Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den kommende ordinære generalforsamling Selskabsmeddelelse nr. 09/2025Intern viden Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den kommende ordinære generalforsamling Interim CEO Lars Rasmussen har i dag informeret Coloplasts bestyrelse om, at han ikke genopstiller som bestyrelsesmedlem ved den kommende ordinære generalforsamling den 4. december 2025. ”På vegne af bestyrelsen vil jeg gerne takke Lars for hans mangeårige engagement i Coloplast. Gennem næsten fire årtiers virke – herunder 10 år som CEO og...
Coloplast interim CEO Lars Rasmussen will step down from the Board at ...
Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting Announcement no. 09/2025Inside information Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting Coloplast interim CEO Lars Rasmussen has today informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. “On behalf of the Board, I want to thank Lars for his unwavering dedication to Coloplast. Through his commitment to the company f...
- Nicolas David
- Stefano Toffano
- Thomas Zlowodzki
SGO COMPAGNIE DE SAINT-GOBAIN SA
EDP EDP-ENERGIAS DE PORTUGAL SA
MT ARCELORMITTAL SA
BVI BUREAU VERITAS SA
BEKB BEKAERT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
ORA ORANGE SA
SSAB A SSAB AB CLASS A
GIVN GIVAUDAN SA
SZG SALZGITTER AG
ITRK INTERTEK GROUP PLC
VOE VOESTALPINE AG
ACX ACERINOX SA
REE RED ELECTRICA CORP. SA
ERA ERAMET SA
DTE DEUTSCHE TELEKOM AG
FAE FAES FARMA S.A.
NDA AURUBIS AG
ANA ACCIONA SA
CIE CIE AUTOMOTIVE S.A.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
AMS AMADEUS IT GROUP SA CLASS A
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
BC BRUNELLO CUCINELLI S.P.A.
COLO B COLOPLAST A/S CLASS B
COL INMOBILIARIA COLONIAL SOCIMI SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
CLNX CELLNEX TELECOM S.A.
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
IDR INDRA SISTEMAS S.A. CLASS A
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
RIO RIO TINTO PLC
UNI UNICAJA BANCO S.A.
BHP BHP GROUP LTD
CASH PROSEGUR CASH SA
HOME NEINOR HOMES SA
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
AMAG AMAG AUSTRIA METALL AG
GEST GESTAMP AUTOMOCION S.A.
GRE GRENERGY RENOVABLES
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
VUL VULCAN ENERGY RESOURCES
SGSN SGS SA
AAL ANGLO AMERICAN PLC
AENA AENA S.M.E. SA
- Nicolas David
- Stefano Toffano
- Thomas Zlowodzki
SGO COMPAGNIE DE SAINT-GOBAIN SA
EDP EDP-ENERGIAS DE PORTUGAL SA
MT ARCELORMITTAL SA
BVI BUREAU VERITAS SA
BEKB BEKAERT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
ORA ORANGE SA
SSAB A SSAB AB CLASS A
GIVN GIVAUDAN SA
SZG SALZGITTER AG
ITRK INTERTEK GROUP PLC
VOE VOESTALPINE AG
ACX ACERINOX SA
REE RED ELECTRICA CORP. SA
ERA ERAMET SA
DTE DEUTSCHE TELEKOM AG
FAE FAES FARMA S.A.
NDA AURUBIS AG
ANA ACCIONA SA
CIE CIE AUTOMOTIVE S.A.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
FDR FLUIDRA S.A.
AMS AMADEUS IT GROUP SA CLASS A
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
BC BRUNELLO CUCINELLI S.P.A.
COLO B COLOPLAST A/S CLASS B
COL INMOBILIARIA COLONIAL SOCIMI SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
CLNX CELLNEX TELECOM S.A.
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
IDR INDRA SISTEMAS S.A. CLASS A
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
RIO RIO TINTO PLC
UNI UNICAJA BANCO S.A.
BHP BHP GROUP LTD
CASH PROSEGUR CASH SA
HOME NEINOR HOMES SA
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
AMAG AMAG AUSTRIA METALL AG
GEST GESTAMP AUTOMOCION S.A.
GRE GRENERGY RENOVABLES
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
VUL VULCAN ENERGY RESOURCES
SGSN SGS SA
AAL ANGLO AMERICAN PLC
AENA AENA S.M.E. SA
- Oliver Metzger
Coloplast A/S - Finanskalender 2025-26
Coloplast A/S - Finanskalender 2025-26 Venligst se vedlagte pdf. For yderligere information og kalenderinvitationer til kommende begivenheder, besøg venligst: Med venlig hilsen,Investor RelationsColoplast A/STel. 4911 1800 For yderligere information, kontakt venligst Investorer og analytikereAnders Lonning-SkovgaardKoncerndirektør, CFOTlf. 4911 1111 Kristine Husted MunkSenior Director, Investor RelationsTlf. 4911 1800 / 4911 3266E-mail: Simone Dyrby HelvindSenior Manager, Investor RelationsTlf. 4911 1800 / 4911 2981E-mail: Presse og medierPeter MønsterSr. Media Relations Manage...
Coloplast A/S - Financial Calendar 2025-26
Coloplast A/S - Financial Calendar 2025-26 Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: Kind regards,Investor RelationsColoplast A/STel. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. Kristine Husted MunkSenior Director, Investor RelationsTel. / Email: Simone Dyrby HelvindSenior Manager, Investor RelationsTel. / Email: Press and mediaPeter MønsterSr. Media Relations ManagerTel. Email: AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenm...
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Acceleratin...
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, ...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; September 26, 2025 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.